Category Archives: Regenerative Medicine

The best pain clinic in Scottsdale, Arizona Pain Specialists, is now offering regenerative medicine injections with platelet rich plasma therapy. The PRP injections represent cutting edge technology in pain management and are showing excellent results for tendon and ligament injuries along with arthritis pain.

Scottsdale, AZ (PRWEB) December 31, 2012

Arizona Pain Specialists continually offers ground breaking technology to patients that is effective and safe. Platelet Rich Plasma is a technology that utilizes a patient's own blood. The blood is spun down using a centrifuge into plasma containing platelets and growth factors. The resulting solution, PRP, is reinjected into the patient's problem area, which helps repair the damage.

There have been numerous studies performed on PRP therapy, and according to the American Academy of Orthopedic Surgeons three professional sports leagues now approve of the use of platelet rich plasma treatment. The therapy is being used to treat tendon injury such as rotator cuff tendonitis, achilles tendonitis, knee, hip and elbow injury.

Along with tendon damage, ligament injuries are also being helped with PRP. This includes the collateral ligaments of the knee and more. Recently, the use of PRP has extended to arthritic conditions as well.

"Platelet rich plasma is great because the risks are low and the treatment calls in the body's own stem cells. So they turn into a form of stem cell injection therapy, and results in initial studies are showing extremely promising results," said David Greene, CEO of the Arizona Pain Network.

Along with providing pain management Scottsdale trusts, Arizona Pain also has clinics in Glendale and Chandler. This makes it convenient to serve those in Phoenix, Mesa, Gilbert, Tempe, Surprise, Goodyear and surrounding areas.

For more information regarding this amazing new technology, call (480) 535-7370.

Jennifer Arizona Pain Specialists (480) 535-7370 Email Information

Go here to see the original:
Best Scottsdale Pain Management Clinic Now Offering Regenerative Medicine With Platelet Rich Plasma Injections

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/z30UCNTkzIQ/the-accuracy-of-adipose-stem-cell-doses.html

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/z30UCNTkzIQ/the-accuracy-of-adipose-stem-cell-doses.html

Arizona Pain Specialists, the leading pain clinics in Phoenix and Scottsdale metropolitan areas, are now offering cutting edge platelet rich plasma injections. Also known as PRP for short, the regenerative medicine injections work well for relieving pain by recruiting the body's stem cells to repair the damaged area.

Phoenix, AZ (PRWEB) December 19, 2012

Regenerative medicine with PRP represents the current state of the art treatment in pain management. Most treatments up until recently have been good at pain relief by masking the problem, rather than repairing it. While these treatments, such as cortisone injections, are excellent at short term pain relief, they are not fixing the actual problem.

Platelet rich plasma actually provides growth factors which have the potential to regenerate damaged cartilage, tendons and ligament. The treatment consists of using the patient's own blood from a simple blood draw, and centrifuging the specimen to obtain the platelets and growth factors in the plasma.

The PRP injection has shown significant benefit in initial studies, including a review by Sampson et al from a 2008 Current Review Musculoskeletal Medicine study. The injections are beneficial for tendinitis of the elbow, shoulder, hip, knee and ankle. Reviews are also showing benefit for arthritis as well.

Regenerative medicine with PRP represents the cutting edge in modern medicine for musculoskeletal conditions. It represents a different approach to treating painful conditions, and Arizona Pain takes pride in offering the latest therapies while taking care to preserve patient safety.

The Board Certified and Fellowship Trained doctors at Arizona Pain Specialists offer platelet rich plasma injections as an outpatient treatment. Phoenix pain management services are available across the valley serving Glendale, Scottsdale, Chandler, Mesa, Surprise, Tempe, Goodyear and more.

More information and scheduling is available at (602) 507-6550.

Jennifer Arizona Pain Specialists (602) 507-6550 Email Information

Original post:
Best Pain Clinics in AZ, Arizona Pain Specialists, Now Offering Regenerative Medicine with Platelet Rich Plasma ...

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing. Mr. Janus primary focus will be to create, market, and sell research products for BioTime and its subsidiaries in the expanding field of regenerative medicine. Mr. Janus has more than 25 years of experience and a proven track record of creating profitable commercial cell-based business.

Jeffrey brings tremendous expertise in regenerative medicine, developing and selling research products and reagents, and building business units, said Michael D. West, PhD, BioTimes Chief Executive Officer. We welcome Jeffrey to the BioTime team and look forward to working together with him in expanding our development, marketing, and sale of research products.

I am honored and excited to be a part of the BioTime team. It is especially gratifying to be working with BioTimes partner LifeMap Sciences, Inc. and their unique and powerful on-line integrated database suite for genomic, biomedical and stem cell research. This in-depth database suite, linked to BioTimes unique PureStem lines of standardized human progenitor cells, gives researchers a comprehensive set of tools to study human embryonic development and stem cell biology. Medical research has always depended upon the availability of standardized research products and information, and BioTime and LifeMap have become leaders in consolidating biomedical information with standardized stem cells.

Mr. Janus was most recently Senior Vice President of Operations at International Stem Cell Corporation (ISCO), where he led the company to discover a process known as parthenogenesis resulting in functional human pluripotent stem cells without the use of fertilized human embryos, and was previously the CEO and founder of Lifeline Cell Technology, LLC, a subsidiary of ISCO. Prior to that, he was a member of the founding team that created Clonetics Corporation and the Clonetics brand of primary human cell products. In addition to his extensive experience in developing and selling cell-based products to the research market, Mr. Janus has led teams of scientists both internally and through external domestic and international collaborations with major academic institutions to conduct research. He has grown several biotechnology companies from the ground up, from licensing or patenting intellectual property, to building teams to develop, manufacture and market products profitably. He has a deep understanding of the process of creating and managing teams and has used the strategic planning process to great success.

Mr. Janus has a Masters Degree in Business Administration from California State University, San Diego and a Bachelor Degree in Biochemistry from the University of California at Davis and is a published author of breakthrough papers in the field of parthenogenesis and stem cell research.

About BioTime, Inc.

BioTime, headquartered in Alameda, Calif., is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc., markets GeneCards, the leading human gene database, and has developed an integrated database suite to complement GeneCards that includes the LifeMap Discovery database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap is also marketing BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc., and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

Original post:
BioTime Announces the Appointment of Jeffrey Janus as Vice President

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC or the Company), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has been named as one of the 10 Ideas That Will Shape The Year in the Christmas and New Year Special issue of the New Scientist, widely considered to be one of the most influential science and technology news magazines in the world.

The list includes innovations in different scientific areas such as health and medicine, climate change, technology and others. ACTs platelet program aims to provide a renewable, donorless source of blood platelets to people in need of platelet transfusions.

Human iPS cells are a game-changer in medicine, said Robert Lanza, M.D., chief scientific officer of ACT. They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets dont contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013.

ACT plans to compare normal and iPS cell-derived platelets in eight healthy volunteers and analyze recovery and survival. Additionally, normal platelets will be compared to human embryonic stem cell-derived platelet cells.

We appreciate this recognition from the New Scientist, commended Gary Rabin, chairman and CEO. It speaks to the growing importance of the stem cell and regenerative medicine sector.

Link to Article in New Scientist: http://www.newscientist.com/article/mg21628965.400-2013-smart-guide-revolutionary-human-stem-cell-trial.html

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

See more here:
New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 ...

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of manufacturing seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells. The paper, scheduled to be published online (ahead of print) at 1600 GMT today in the peer-reviewed journal Regenerative Medicine, characterizes the seven cell types generated using BioTimes proprietary PureStemTM technology. The study compared the novel cells with adult stem cells, known as mesenchymal stem cells (MSCs), and revealed properties of the new cell lines that are suggestive of a wide array of future applications in the practice of orthopedic medicine.

In the study published today, it was demonstrated that BioTimes cells, which can be manufactured on an industrial scale, are progenitors to diverse skeletal tissues of the human body. These cell lines bear diverse molecular markers that distinguish them from each other and from MSCs. The molecular markers of BioTimes cell lines suggest the lines may therefore be applicable to the repair of different types of bone, cartilage, and tendon for the treatment of degenerative diseases afflicting these tissue types such as non-healing bone fractures, osteoarthritis and degeneration of intervertebral discs, and tendon tears (tendinosis).

Chronic orthopedic disorders such as osteoarthritis, degeneration of the discs in the spine, osteoporosis, and tendon tears are among the leading complaints and causes of disability in an aging society. The recent isolation of new pluripotent stem cells such as human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells opens the door to the manufacture of all of the cell types in the human body on an industrial scale. These achievements in the emerging field of regenerative medicine have made it feasible to introduce new modalities of repairing these and other tissues in the body.

As promising as these new stem cells may be for eventual human tissue repair, there has been little progress to date in identifying new ways to generate pure populations of the diverse cellular components of the human body using methods that are also compatible with industrial-scale manufacture. To address this need, BioTime scientists developed a novel and proprietary manufacturing process. These isolated PureStemTM(previously ACTCellerateTM) cell lines allow for the scale-up of more than 200 highly purified and identified cell types.

In today's publication, BioTime scientists reported on seven PureStemTM cell lines representing diverse cells of the developing human skeleton. One of these cell lines, 4D20.8, was previously shown by BioTime scientists to exhibit site-specific markers of craniofacial mesenchyme, and in particular, markers of proximal mandibular mesenchyme. This tissue type is of significance in that it naturally produces one of the strongest joint cartilages of the body. In todays report, this line was compared to the BioTimes lines 7PEND24, 7SMOO32, E15, MEL2, SK11, SM30, and to other commonly studied MSCs. BioTimes cell lines displayed markers that indicated the cells were progenitors of diverse cartilage, bone, and tendon cell types in the body.

There remains the need for safe methods of manufacturing cells at a high degree of purity and site-specific identity, in addition to an FDA-approvable combination with a matrix to facilitate the stable transplantation of those cells into the body. BioTimes HyStem technology is designed to be an effective means of transplanting cells in an injectable liquid that can polymerize safely in the body into a tissue construct. BioTime anticipates that during the first quarter of 2013, a submission of a Phase I safety trial in humans will be made to the appropriate European Committee for review and approval of HyStem formulated for the delivery of autologous fat-derived cells for skin applications, a product called Renevia. In todays publication, the seven novel osteochondral cell lines were demonstrated to be successfully differentiated in HyStem in laboratory experiments, supporting the potential use of the product together with these and other PureStemTM cell lines in combination products.

The studys demonstration of the manufacture of diverse site-specific tissue progenitors from pluripotent stem cells serves to highlight the utility of LifeMap Discovery, a powerful new database that provides a roadmap to the complex fabric of cells constituting the human body. In todays publication, BioTime and LifeMap scientists collaborated to map the molecular markers of the published PureStemTM cell lines within the database, thus making the lines available for the research community in the context of the human developmental tree.

We are gratified to finally report in a scientific publication the power of monoclonal human embryonic progenitor cell lines to scale diverse cell types of the human body, said Michael D. West, Ph.D., BioTime's Chief Executive Officer. Our confidence that many other cell types of the human body can be manufactured in this manner is the reason for our focus on this platform and for participating in building LifeMap DiscoveryTM to help the medical research community navigate this fascinating yet complex network of product development.

Arnold Caplan, Ph.D., OrthoCyte's Chief Scientific Officer and Director of the Skeletal Research Center at Case Western Reserve University, commented that the paper by Sternberg and colleagues emphasizes the scalability of clonal human embryonic stem cell-derived cell lines for musculoskeletal tissue engineering.The analysis at the molecular level of the biological markers gives us confidence that these groups of cells can be used for cartilage repair and regeneration. The amount of cells that can be generated is really practical for human musculoskeletaltissue regeneration.

Here is the original post:
BioTime Reports Isolation of Seven Diverse Cartilage and Bone Cell Types From Human Embryonic Stem Cells

For other things, however,  the people around you have such high expectations you'll do them that you only lose points if you don't but gain very little if you do.  For you, this may be true of the dishes.  Certainly I've always maintained this is true for Valentine's Day.  Get flowers and you simply maintain the relationship's status quo; fail to do anything and you lose big points fast.  

The result is "Why the stem cell sector must engage with social media".  What I attempted to succinctly outline are the ways social media primarily benefit one's career and organization or company.


"I can tell you without the slightest hesitation of conviction – having experienced it myself and seen it repeated countless times – is that active and successful social media engagement translates into:

• Unparalleled learning: accessing more information relevant to your discipline, specialty and company than you otherwise will. 
• Enhanced profile: higher profile within your industry, profession, specialty and community. Social media is not the only way to build a profile but it can be very effective.
• Wider network: more touch points and meaningful relationships with people than you otherwise will accomplish by any other means combined."

"In order to create the kinds of perceptions and solicit the kinds of actions we want from the world around us, we must engage the world around us. The world around us is engaging online. 

For all kinds of selfish and selfless reasons you, your company or organization and your career will benefit from you engaging there too."

and this prediction:

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/k7ANTnLXNjc/the-roi-on-pant-wearing-and-other.html

I welcome comments and feedback. 


1. In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) we must do more to help patients distinguish between non-compliant cell therapy treatments (and providers) which are more or less risky. 


2. Whatever we do in response to this issue should be done with an eye to being practical and helpful to patients in the real-life context of their decision about whether or not to buy a non-complaint cell therapy.


3. Our response to this issue should be based on a risk-based approach recognizing that not all non-compliance is created equal.  We should create a framework for risk-based analysis (both for us and our audiences) and focus initiatives around those which present the highest risk.


4. We recognize the problem of non-compliant cell therapies is not just a problem that exists in jurisdictions with little, no, or poor regulation but that is a growing problem even in the most highly regulated jurisdictions meaning the solution cannot be regulated it depends on education and enforcement.


5. We recognize regulatory agencies cannot enforce non-compliance on their own.  We as an industry need to complement their efforts through our own standards and enforcement.


6. Stakeholder groups should support the formation of a multi-organizational  initiative to, based on a risk-based assessment, spotlight the categories or signs of highest-risk offenders for use by patients and/or their physicians in identifying  whether or not treatments (and providers) they may be considering fall into the that category associated with the highest level of risk.

What do you think?

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/wkSMxAV9938/a-proposed-6-step-platform-for-cell.html